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Abstract: Human embryonic stem cells (hESCs) are pluripotent stem cells with long-lasting capacity to self-renew and
differentiate into various cell types of endodermal, ectodermal or mesodermal origin. Unlike mouse ESCs (mESCs), which
can be maintained in an undifferentiated state simply by adding leukemia inhibitory factor (LIF) into the culture medium,
hESCs are notorious for the sustained willingness to differentiate and not yet clearly defined signaling pathways that are crucial
for their "stemness". Presently, our knowledge involves only limited number of growth factor signaling pathways that appear
to be biologically relevant for stem cell functions in vitro. These include BMP, TGFβ, Wnt, and FGF signaling pathway. The
purpose of this review is to summarize recent data on the expression of FGFs and their receptors in hESCs, and critically
evaluate the potential effects of FGF signals for their undifferentiated growth and/or differentiation in context with our current
understanding of FGF/FGFR biology. 
Key words: Basic FGF - Human embryonic stem cells - Self-renewal - Differentiation
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Fibroblast growth factors (FGFs) constitute a large fa-
mily of signaling polypeptides that are expressed in
various cell types from early embryos to adults. Since
the first discovery of FGF in 1974 [14], 22 distinct
members of the FGF family have been described [re-
viewed in 22]. FGF family members range from 16 to
34 kDa and share 13-71% amino acid identity. Across
vertebrates, FGFs are highly conserved and promiscu-
ously bind to four high-affinity transmembrane receptor
tyrosine kinases, denoted as FGFR1, 2, 3, and 4. In
addition to high-affinity FGFRs, FGFs interact also with
extracellular matrix-derived or membrane-bound he-
paran sulfate proteoglycans or their fragments that either
potentiate or inhibit FGF activity [11, 16]. To date, four
known members of the signaling FGFR family have a
similar structure that is comprised of hydrophobic leader
sequence, two or three immunoglobulin-like domains,
acidic box, short transmembrane region, and two tyro-
sine kinase domains. Common hallmark of FGFR family
is that the receptor diversity is controlled by alternative
splicing, resulting in the generation of multiple splice
variants (Fig. 1). These splice variants of FGFRs ex-
hibit differential ligand-binding characteristics and
are expressed in differentiation- and tissue-specific
manner [reviewed in 5].
During embryonic development, FGFs function in
multiple biological processes including cell prolifera-
tion, differentiation, and migration [2]. In mammalian
embryos, members of FGF family are expressed in many
cell types, but the timing of expression varies. In addi-
tion, several FGFs are present exclusively in embryonic
tissues, whereas others, including basic FGF (bFGF or
FGF-2), are expressed in embryonic and adult tissues.
In the adult organism, FGFs represent important ho-
meostatic factors and play a role in response to injury
and tissue repair [6]. Importantly, aberrant expression of
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some FGFs may lead to malignant transformation and
may contribute to the pathophysiology of cancer, e.g. by
regulating apoptosis or neovascularization [21, 33]. As
mentioned above, an important feature of FGF biology
is tissue-specific alternative splicing and expression of
the receptors that ensure differential action of FGFs
during development. In this regard, FGFR1 plays an
essential role in early development, mainly in mesoderm
patterning and cell migration during gastrulation, and it
is also involved in cell differentiation at several levels
during early stages of organogenesis. Conversely,
FGFR2 is expressed and functions later during orga-
nogenesis, and FGFR3 is involved in differentiation of
oligodendrocytes and astrocytes in central nervous sys-
tem, and also regulates bone formation. FGFR4 is highly
expressed in the definitive endoderm and embryonic
muscle plate [5].
The activation of FGFRs involves two different li-
gands, FGFs and heparan sulfate proteoglycans or their
side chains. Cooperation between both types of ligands
is essential as the binding of FGFs or heparan sulfate
proteoglycans alone is insufficient for FGFR dimeriza-
tion and initiation of downstream signaling. The signal
cascade downstream of FGFRs involves tyrosine phos-
phorylation of the docking protein FRS2 followed by
recruitment of several Grb2 molecules. Activated Grb2
molecules bound to FRS2 recruit the nucleotide ex-
change factor SOS. The formation of FRS2-Grb2-SOS
complexes results in activation of the Ras-Raf-MAPK
signaling pathway followed by cell response. Parallel,
phosphorylated FGFRs activate also PLCγ-PKC path-
way and Grb2 molecule recruits the docking protein
Gab1 that activates PI3K-Akt cell survival pathway.
Therefore, FGF signaling through FGFRs is mediated
primarily by assembly of a multidocking protein com-
plex and involves several layers of control [28]. The
complexity of FGF signaling via FGFRs is schematized
in Figure 2.
Expression of FGF and FGFR in hESCs
It is widely accepted that hESCs should be maintained
on feeder layers of mouse embryonic fibroblasts or other
suitable feeder cells. Also culture medium contains
bFGF, in order to sustain self-renewal of hESCs and
their capacity to differentiate (Fig. 3). Although it is
likely that exogenous bFGF supports growth of undif-
ferentiated hESCs [1, 34], the mechanism of bFGF
action is not yet clearly established. 
The first step to understanding the action of members
of FGF family, including bFGF, is to determine the
expression of individual components of FGF signaling
pathway. As one of the most powerful tools of modern
biology, large scale transcriptional profiling of undif-
ferentiated and differentiating hESCs provides the op-
portunity (1) to identify genes that are involved in the
mechanisms responsible for pluripotency or early dif-
ferentiation events, and (2) to develop unique molecular
signatures of independently-derived hESC lines. Using
cDNA microarray analysis, several groups have de-
tected elevated levels of key components of the FGF
signaling pathway in undifferentiated hESCs compared
with their differentiated counterparts. These include
bFGF, FGF-11, and FGF-13, as well as FGFR1, FGFR2,
FGFR3, and FGFR4 [9, 13, 24, 27, 29]. More recently,
transcriptomes of undifferentiated hESCs and hESC-
derived embryoid bodies (EBs) were compared by mass-
ively parallel signature sequencing (MPSS) that permits
more complete mapping than conventional cDNA
microarrays [32]. MPSS clearly shows that hESCs ex-
press substantial levels of mRNAs coding bFGF and its
three high-affinity receptors, FGFR1, FGFR3, and
FGFR4. In addition, hESCs express mRNA for docking
protein FRS2 that represents a major target of activated
FGFRs (see Figure 2). Interestingly, FGF4 that is highly
expressed and functional in mESCs, is absent in hESCs.
In concert with these bulk analyses of the transcrip-
tome, we recently determined using Western blot ana-
lysis that undifferentiated as well as differentiating
hESCs are abundant in several molecular-mass isoforms
of FGF-2, including those that are exportable (18 kDa
low molecular-mass isoform) or localize into the nu-
cleus (22, 22.5, and 24 kDa high molecular-mass iso-
forms). Interestingly, using quantitative RT-PCR we
also revealed that the expression of FGFRs in undif-
ferentiated cells follows a specific pattern, with FGFR1
being the most abundant receptor and other receptors
showing lower expression in the order: FGFR3>
FGFR4>FGFR2. When hESCs are induced to differen-
tiate, expression of all four FGFRs remarkably in-
creases; with FGFR1 being elevated about six-fold,
FGFR2 about two-fold, and FGFR3 and FGFR4 about
seven-fold [10]. Together, several groups including our
own have clearly demonstrated that hESCs are well
equipped to accept and transmit FGF signals. Taken
together, it became obvious for the first time that, thanks
to the expression of multiple exportable and nuclear
forms of FGF, FGF signaling pathway in hESCs may
function in an autocrine manner, and that the capacity to
accept FGF signals may increase when cells undergo
differentiation. 
Effects of bFGF on growth of undifferentiated
hESCs
Since their first derivation in 1998 [30], hESCs are
routinely cultured on feeder layers of mouse or human
fibroblasts in medium that is supplemented with bFGF
at the concentration of 4-5 ng/ml. Due to expected
clinical requirements, many laboratories have begun
culturing hESCs in a feeder-free system. In this case they
increased the concentration of bFGF to 8 ng/ml [4].
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Fig. 2. Signaling pathways activated by FGFs. Stimulatory and inhibitory stimuli are depicted in black and red, respectively. The abbreviations
for all elements of canonical FGFR intracellular signaling pathway are accessible at http://stke.sciencemag.org/cgi/cm/stkecm;CMP_15049.
Adapted from Schlessinger, 2004.
Fig. 1. Structural features of the FGFR and action of bFGF. I. Exogenous bFGF binds to its high-affinity receptors and triggers "classical"
transduction pathway that consists of recruitment, assembly, and phosphorylation/activation (P) of downstream signaling proteins. In addition,
FGF action could be enhanced or inhibited by heparan sulfate proteoglycans or their fragments.  II. Low molecular-mass isoform of bFGF
binds to its high-affinity receptors, principally FGFR1, and the resulting complex is internalized and translocated to the nucleus. Nuclear low
molecular-mass bFGF may function by activating genetic programs related to cell growth, differentiation, and adaptive responses to culture
conditions. III. Endogenously produced low molecular-mass bFGF lack an obvious signal sequence and could be released only in complex
with other molecules (e.g. HSP 27) by exocytotic mechanism that is independent of the endoplasmatic reticulum-Golgi pathway. Then
exported bFGF acts in an autocrine or paracrine manner. IV. Endogenously produced high molecular-mass bFGF associates with
bFGF-Interacting Factor (FIF) and is directly transported to the nucleus where mediates the pro-survival and anti-apoptotic activities. 
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Obvious interpretation of the effects on hESCs is that
bFGF supports growth of undifferentiated cells and in-
creases cloning efficiency. Although such promoting
effect of exogenous bFGF on growth of undifferentiated
hESCs has been reported by several groups [1, 4, 18, 26,
34], the exact signaling mechanism remains unknown.
It becomes apparent that hESCs , similarly to other types
of in vitro expanded stem cells, may employ intracrine
or autocrine signaling pathways to retain their "stem-
ness" in addition to exogenous growth factor signals. On
the other hand, certain autonomous signaling pathways
may also be activated when hESCs are induced to dif-
ferentiate by various differentiation stimuli. Importan-
tly, it is of note that hESCs represent a greatly in vitro
expanded cell population that is only reminiscent to
inner cell mass-derived primitive ectoderm in the em-
bryo. Therefore, at least some signaling pathways in
hESCs might not have relevance in vivo and should be
studied only in the context with future clinical applica-
tions.
Recently, Xu et al. [36] and Wang et al. [31] have
shown that noggin combined with bFGF at extremely
high concentration (40 ng/ml) supports the undif-
ferentiated proliferation of hESCs in the absence of
fibroblast feeder cells. As hESCs cultured in fibro-
blast-unconditioned medium show high levels of bone
morphogenetic protein (BMP) signaling activity com-
pared to hESCs maintained in fibroblast-conditioned
medium, this effect was explained in a such way that
BMP antagonist noggin synergizes with bFGF to
repress trophoblast-inducing BMP signaling and
thus sustains undifferentiated growth of hESCs. It
has been reported that also bFGF alone is sufficient
to maintain hESC self-renewal in the absence of
feeder cells [35]. 
Notably, the effect of bFGF on undifferentiated
growth of hESCs is apparent only at very high molar
concentration (40 ng/ml represents 2.4 nM) that may be
irrelevant to the binding capacity of the FGFRs ex-
pressed in hESCs. For instance, it has been reported that
human leukemia K562 cells that are known for their high
expression of FGFRs and high FGF binding activity
have about 1600 high-affinity binding sites per cell [27].
Also in bFGF-high responsive aortic endothelial cells
the expression of FGFRs is at the same order of magni-
tude, with about 5000 FGFR sites per cell [23]. More-
over, as mentioned earlier, the binding of bFGF to
hESCs might be significantly modulated by membrane-
bound or soluble low-affinity binding sites that can
either potentiate or inhibit bFGF biological activity [11,
16]. However, currently there is no information on the
expression and action of low-affinity FGF receptors in
hESCs. This very important issue regarding the capacity
of undifferentiated hESCs to accept bFGF signals re-
mains to be addressed.
Although several groups have suggested effect of
exogenous bFGF on the maintenance of proliferating
hESCs in the undifferentiated state, proliferation rate
itself was found not to be significantly affected. In
fact, some other differences in hESCs cultures de-
pending on the concentration of exogenous bFGF
were observed by us and by other groups. These dif-
ferences were mainly manifested by the growth of
smaller cells and ability of cells to spread on the feeder
layer of mouse fibroblasts. Interestingly, in our hands
the outgrowth of hESC colonies in medium containing
10 or 20 ng/ml bFGF was reduced compared to the
outgrowth in medium without or with only 5 ng/ml
bFGF. This observation is in agreement with studies
on various cell types indicating that bFGF has a poten-
tial to modulate cell attachment and spreading. This
may happen either by induction of cell adhesion mole-
cules [7, 12, 15] or via complexing FGFR1 expressed on
target cells with feeder cell-associated heparan sulfates
[25]. 
Fig. 3. Morphology of hESCs. HESCs cultured on feeder layers of
mouse embryonic fibroblasts (A) and human foreskin fibroblasts (B).
Bars = 50 µm. 
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Our recent insights into the mechanisms of
FGF/FGFR signaling in hESCs
It is apparent that bFGF added to culture media may
stimulate hESCs only via their high-affinity receptors.
In contrast, bFGF produced endogenously by hESCs
may function in two ways depending on the presence or
absence of the nuclear localization sequence: high mole-
cular-mass isoforms can be directly targeted to the nu-
cleus and operate independently of cell surface receptors
in an intracrine manner; whereas the low molecular-
mass isoform may be exported from the cells and act via
FGFRs as an autocrine or paracrine factor. 
We have shown that stimulation of hESCs by bFGF
at the concentration that is routinely used for undifferen-
tiated hESC culture leads to tyrosine phosphorylation of
various proteins and to activation of extracellular signal-
regulated kinases, ERK1/2, in particular. However, we
also noted that undifferentiated hESCs maintained for
several days in bFGF-free medium possess an unexpec-
tedly high basal level of phosphorylation of ERK1/2,
which contrasts with the undetectable ERK1/2 phospho-
rylation typically demonstrated by mESCs. We hypo-
thesized that such constitutive activation of ERK1/2
could be caused, at least in part, by unusually high
expression of exportable and nuclear isoforms of bFGF
in hESCs conferring a reduced dependency of ERK
activity on extracellular signals.
To test whether autocrine FGF signaling is important
for growth of undifferentiated hESCs, we treated hESCs
cells with the pharmacological inhibitor of FGF receptor
tyrosine kinases, SU5402, which specifically interacts
with intracellular catalytic domain of FGFRs [20]. After
2 days of continuous exposure to SU5402, cells in the
centers of some colonies acquired differentiated mor-
phology. Upon further culture in the presence of
SU5402, such morphology, accompanied by a loss of
markers of undifferentiated cells Oct-4 and SSEA-4,
developed in all hESC colonies. Concomitantly, de-
creased phosphorylation of mitogen-activated protein
kinase kinase (MEK1/2) and its substrate ERK1/2 were
both observed in cells that were maintained in medium
with the inhibitor. Similar effect was observed in hESCs
irrespectively of the presence or absence of recombinant
bFGF. Importantly, the occurrence of differentiated
cells was accompanied by up-regulation of cyclin-de-
pendent kinase inhibitor p27, a common event that char-
acterizes differentiation of cells of early embryonic
origin [3], and by a slower proliferation. Moreover,
differentiation process was manifested by up-regulation
of TROMA-1, a marker for primitive endoderm, and of
nestin, a marker for developing neuroepithelium and for
epithelial precursors in the embryonic pancreas. 
As mentioned above, hESCs contain significant
amount of nuclear high molecular-mass isoforms of
bFGF. The nuclear accumulation of bFGF is linked with
post-translational methylation, which is important for
protein-protein and protein-RNA interactions [17].
Moreover, some data also suggest that nuclear localiza-
tion of bFGF accounts for the regulation of genes that
are involved in the pro-survival phenotype of cells [8].
If this is true also for hESCs remains to be investigated.
We conclude that undifferentiated hESCs possess
functional FGF signaling pathway that can basically
operate in two different ways: (a) autocrine via low
molecular-mass bFGF and FGFRs and (b) intracrine
through translocation of high molecular-mass bFGF into
the nucleus. We propose that autocrine FGF signaling
pathway is unconditionally vital for proliferation of
hESCs in the undifferentiated state. 
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